Molecular Partners (NASDAQ:MOLN) Now Covered by Lifesci Capital

Lifesci Capital assumed coverage on shares of Molecular Partners (NASDAQ:MOLN) in a report issued on Tuesday,Benzinga reports. The brokerage issued an outperform rating and a $12.00 target price on the stock.

Molecular Partners Stock Performance

Molecular Partners stock opened at $4.62 on Tuesday. The stock’s 50 day moving average price is $5.09 and its 200 day moving average price is $5.33. The firm has a market capitalization of $186.28 million, a PE ratio of -2.15 and a beta of 1.06. Molecular Partners has a one year low of $3.32 and a one year high of $12.70.

Molecular Partners (NASDAQ:MOLN) last released its quarterly earnings results on Thursday, March 6th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.11. Molecular Partners had a negative return on equity of 39.31% and a negative net margin of 1,043.01%. On average, analysts forecast that Molecular Partners will post -1.93 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Molecular Partners

An institutional investor recently raised its position in Molecular Partners stock. BVF Inc. IL boosted its holdings in shares of Molecular Partners AG (NASDAQ:MOLN) by 205.5% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,353,968 shares of the company’s stock after purchasing an additional 910,747 shares during the quarter. BVF Inc. IL owned approximately 3.35% of Molecular Partners worth $6,458,000 at the end of the most recent quarter. Institutional investors and hedge funds own 26.55% of the company’s stock.

Molecular Partners Company Profile

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.